CA3182970A1 - Redirection of tropism of aav capsids - Google Patents
Redirection of tropism of aav capsidsInfo
- Publication number
- CA3182970A1 CA3182970A1 CA3182970A CA3182970A CA3182970A1 CA 3182970 A1 CA3182970 A1 CA 3182970A1 CA 3182970 A CA3182970 A CA 3182970A CA 3182970 A CA3182970 A CA 3182970A CA 3182970 A1 CA3182970 A1 CA 3182970A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- aav capsid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023927P | 2020-05-13 | 2020-05-13 | |
| US63/023,927 | 2020-05-13 | ||
| US202063122300P | 2020-12-07 | 2020-12-07 | |
| US63/122,300 | 2020-12-07 | ||
| PCT/US2021/025061 WO2021230987A1 (en) | 2020-05-13 | 2021-03-31 | Redirection of tropism of aav capsids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3182970A1 true CA3182970A1 (en) | 2021-11-18 |
Family
ID=75639982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3182970A Pending CA3182970A1 (en) | 2020-05-13 | 2021-03-31 | Redirection of tropism of aav capsids |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US12630842B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4149955A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7731909B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230022175A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116096734A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021273447B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022023106A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3182970A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022016156A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298001A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014256A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20230767A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI900553B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021230987A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE23193606T1 (de) * | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| WO2020102645A1 (en) * | 2018-11-16 | 2020-05-22 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus for treating pompe disease |
| US12630842B2 (en) | 2020-05-13 | 2026-05-19 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| US20230295238A1 (en) * | 2020-07-23 | 2023-09-21 | The Scripps Research Institute | Insulin receptor-mediated enhancement of gene transfer |
| EP4291654A2 (en) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20240384242A1 (en) * | 2021-09-03 | 2024-11-21 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| EP4413019A2 (en) * | 2021-10-07 | 2024-08-14 | RegenxBio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| EP4426716A1 (en) | 2021-11-02 | 2024-09-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2023092002A2 (en) * | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis and disorders associatedwith the spinal cord |
| EP4433169A1 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| US20250049955A1 (en) | 2021-11-17 | 2025-02-13 | Voyager Therapeutics, Inc. | Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| EP4440696A1 (en) * | 2021-12-01 | 2024-10-09 | Shape Therapeutics Inc. | Functional aav capsids for systemic administration |
| US20250346920A1 (en) | 2022-01-25 | 2025-11-13 | Voyager Therapeutics, Inc. | Baculovirus expression system |
| EP4473001A1 (en) * | 2022-02-01 | 2024-12-11 | The Broad Institute, Inc. | Adeno-associated viral vectors and uses thereof |
| JP2025507338A (ja) | 2022-02-08 | 2025-03-18 | ボイジャー セラピューティクス インコーポレイテッド | Aavカプシドバリアント及びその使用 |
| WO2023194796A2 (en) * | 2022-04-04 | 2023-10-12 | Vectory B.V. | Recombinant aav capsid proteins |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023220476A2 (en) * | 2022-05-13 | 2023-11-16 | The Broad Institute, Inc. | Adeno-associated viral vectors and uses thereof |
| EP4526324A1 (en) * | 2022-05-18 | 2025-03-26 | The Broad Institute, Inc. | Engineered viral capsids with increased stability and methods of use thereof |
| EP4532515A1 (en) | 2022-06-02 | 2025-04-09 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| US20250243263A1 (en) | 2022-06-22 | 2025-07-31 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CA3263767A1 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| JP2025531824A (ja) * | 2022-09-09 | 2025-09-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 受容体リガンドをタイリングするディスプレイされたペプチドを介したトロピズムのリプログラミング |
| JP2025535203A (ja) | 2022-09-15 | 2025-10-23 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| AU2023364350A1 (en) | 2022-10-19 | 2025-06-05 | Affinia Therapeutics Inc. | Recombinant aavs with improved tropism and specificity |
| AU2023378899A1 (en) | 2022-11-13 | 2025-06-26 | Alexion Pharma International Operations Limited | Gene therapy for frontotemporal dementia |
| CN118420721A (zh) * | 2023-01-31 | 2024-08-02 | 上海朗昇生物科技有限公司 | 一种组织嗜性的腺相关病毒衣壳及其用途 |
| AU2023427408A1 (en) | 2023-02-02 | 2025-09-04 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| JP2026509271A (ja) | 2023-03-10 | 2026-03-17 | ダイノ セラピューティクス,インコーポレーテッド | カプシドポリペプチドおよびその使用方法 |
| CN120660140A (zh) * | 2023-03-27 | 2025-09-16 | 浙江大学 | 氨基酸序列的生成与筛选方法及其系统 |
| WO2024226761A2 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2024226790A1 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| EP4705324A1 (en) | 2023-05-02 | 2026-03-11 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| JP2026515815A (ja) | 2023-05-03 | 2026-05-19 | ボイジャー セラピューティクス インコーポレイテッド | Cdkl5欠損に関連する障害の治療のための組成物及び方法 |
| WO2024229389A1 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2024229125A2 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to frataxin deficiency |
| WO2024229164A2 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| EP4705486A1 (en) | 2023-05-03 | 2026-03-11 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency |
| WO2024229173A2 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| JP2026515970A (ja) | 2023-05-04 | 2026-05-19 | ボイジャー セラピューティクス インコーポレイテッド | Aavカプシドバリアント及びその使用 |
| WO2025038805A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025038800A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to frataxin deficiency |
| WO2025038796A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to cdkl5 deficiency |
| WO2025038795A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| WO2025038802A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| WO2025038430A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| KR20260082361A (ko) | 2023-08-31 | 2026-06-04 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 폴리펩타이드 및 이의 사용 방법 |
| CN119569833B (zh) * | 2023-09-06 | 2026-06-16 | 北京锦篮基因科技股份有限公司 | 靶向骨骼肌的aav衣壳蛋白变体及其用途 |
| CN117264912A (zh) * | 2023-09-25 | 2023-12-22 | 中国科学院深圳先进技术研究院 | 一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用 |
| WO2025071848A1 (en) * | 2023-09-26 | 2025-04-03 | Kate Therapeutics, Inc. | Liver detargeted capsids |
| WO2025072698A2 (en) * | 2023-09-27 | 2025-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Aav9 vectors and capsid polypeptides for use in treating cns disorders |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025122548A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to cdkl5 deficiency |
| WO2025122543A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency |
| WO2025122536A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| WO2025122530A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025122532A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| WO2025122644A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| AR134555A1 (es) | 2023-12-05 | 2026-01-28 | Voyager Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina |
| WO2025137219A1 (en) | 2023-12-21 | 2025-06-26 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| WO2025147436A1 (en) | 2024-01-03 | 2025-07-10 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2025194082A1 (en) * | 2024-03-15 | 2025-09-18 | The Children's Medical Center Corporation | Compositions and methods for delivering nucleic acids to podocytes |
| WO2025207954A1 (en) * | 2024-03-27 | 2025-10-02 | General Medicines Llc | Compositions and methods for improved adeno-associated viral gene therapy |
| CN118324853B (zh) * | 2024-04-03 | 2025-03-14 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2025214359A1 (en) * | 2024-04-09 | 2025-10-16 | Hangzhou Jiayin Biotech Ltd. | A novel aav variant |
| WO2025235734A2 (en) | 2024-05-09 | 2025-11-13 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2026012095A1 (en) * | 2024-06-21 | 2026-01-15 | Westlake Genetech. Ltd. | Adeno-associated virus variant capsids |
| WO2026010722A1 (en) | 2024-07-03 | 2026-01-08 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2026050402A1 (en) * | 2024-08-29 | 2026-03-05 | Kate Therapeutics, Inc. | Liver de-targeted muscle tropic capsids |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026096599A1 (en) | 2024-10-30 | 2026-05-07 | Neurocrine Biosciences, Inc. | Compositions and methods for delivering syntaxin-binding protein-1 |
| WO2026096611A1 (en) | 2024-10-30 | 2026-05-07 | Neurocrine Biosciences, Inc. | Compositions and methods for delivering cyclin-dependent kinase-like 5 protein |
| WO2026096603A1 (en) | 2024-10-30 | 2026-05-07 | Neurocrine Biosciences, Inc. | Compositions and methods for delivering syntaxin-binding protein-1 |
| WO2026096600A1 (en) | 2024-10-30 | 2026-05-07 | Neurocrine Biosciences, Inc. | Compositions and methods for delivering cyclin-dependent kinase-like 5 protein |
| WO2026101977A1 (en) * | 2024-11-06 | 2026-05-15 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (226)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2640638B1 (fr) | 1988-12-20 | 1991-02-15 | Commissariat Energie Atomique | Bioreacteur et dispositif pour la culture de cellules animales |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US5741657A (en) | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
| US5756283A (en) | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US6506379B1 (en) | 1995-06-07 | 2003-01-14 | Ariad Gene Therapeutics, Inc. | Intramuscular delivery of recombinant AAV |
| CA2264482A1 (en) | 1996-09-06 | 1998-03-12 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| EP0968284B1 (en) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
| WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| ATE286138T1 (de) | 1998-03-20 | 2005-01-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren |
| US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| FR2786478B1 (fr) | 1998-11-30 | 2000-12-22 | Commissariat Energie Atomique | Confinement du cesium et/ou du rubidium dans des ceramiques apatitiques |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
| JP2003501067A (ja) | 1999-06-02 | 2003-01-14 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ヘルパーウイルスを要求する組み換えウイルス産生のために有用な組成物及び方法 |
| WO2001023001A2 (en) | 1999-09-29 | 2001-04-05 | The Trustees Of The University Of Pennsylvania | Rapid peg-modification |
| US6365394B1 (en) | 1999-09-29 | 2002-04-02 | The Trustees Of The University Of Pennsylvania | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| WO2002081711A1 (en) | 2001-04-06 | 2002-10-17 | Cropdesign N.V. | The use of double and opposite recombination sites for the single step cloning of two dna segments |
| EP1390490B1 (en) | 2001-05-24 | 2009-04-15 | Genzyme Corporation | Muscle-specific expression vectors |
| EP1463805B1 (en) | 2001-12-17 | 2014-10-22 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| US6845866B2 (en) | 2002-10-10 | 2005-01-25 | N. Henning Zieger | Dispenser |
| US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| CN101410519B (zh) | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| WO2005017101A2 (en) | 2003-05-19 | 2005-02-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH | Avian adenoassociated virus (aaav) and uses thereof |
| JP4559429B2 (ja) | 2003-05-21 | 2010-10-06 | ジェンザイム・コーポレーション | 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法 |
| PL2657248T3 (pl) | 2003-06-19 | 2017-09-29 | Genzyme Corporation | Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie |
| WO2005001103A2 (en) | 2003-06-20 | 2005-01-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| WO2005056807A2 (en) | 2003-12-04 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Bovine adeno-associated viral (baav) vector and uses thereof |
| US20060166363A1 (en) | 2004-01-27 | 2006-07-27 | Sergei Zolotukhin | Modified baculovirus expression system for production of pseudotyped rAAV vector |
| CA2566286A1 (en) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| PT3272872T (pt) | 2005-10-20 | 2020-06-26 | Uniqure Ip Bv | Vetores aav melhorados produzidos em células de insetos |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| ES2385679T3 (es) | 2006-08-24 | 2012-07-30 | Virovek, Inc. | Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos |
| EP2158211B1 (en) | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
| EP2058401A1 (en) | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| WO2010005001A1 (ja) | 2008-07-09 | 2010-01-14 | 株式会社 東芝 | X線管用ターゲットおよびそれを用いたx線管、x線検査装置ならびにx線管用ターゲットの製造方法 |
| DE102008060558B4 (de) | 2008-12-04 | 2013-09-26 | Eduard Buzetzki | Verfahren zum katalytischen Cracken von Pflanzenölen und tierischen Fetten |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| WO2011101869A1 (en) | 2010-02-22 | 2011-08-25 | Transgene Biotek Ltd. | Adeno-associated virus 2/8 - micro rna-101 therapy for liver cancer |
| CA2793309A1 (en) | 2010-03-17 | 2011-09-22 | Anaptysbio, Inc. | Method of producing transcripts using cryptic splice sites |
| DK2561073T3 (en) | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| US10415056B2 (en) | 2010-11-10 | 2019-09-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
| CA2826273C (en) | 2011-02-10 | 2021-11-02 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| US20140359799A1 (en) | 2011-12-23 | 2014-12-04 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
| US9644205B2 (en) | 2012-04-25 | 2017-05-09 | The Regents Of The University Of California | Synthetic promoter for modulating gene expression |
| PL2900686T3 (pl) | 2012-09-28 | 2021-01-25 | The University Of North Carolina At Chapel Hill | Wektory aav ukierunkowane na oligodendrocyty |
| EP2940131B1 (en) | 2012-12-25 | 2019-02-20 | Takara Bio Inc. | Aav variant |
| WO2014124282A1 (en) | 2013-02-08 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Enhanced aav-mediated gene transfer for retinal therapies |
| ES2926774T3 (es) | 2013-03-15 | 2022-10-28 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores AAV de doble unión de glicano |
| US11136557B2 (en) | 2013-05-31 | 2021-10-05 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| LT3137497T (lt) | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| RU2668395C9 (ru) | 2014-07-11 | 2018-10-29 | Хуавей Текнолоджиз Ко., Лтд. | Сетевое устройство, устройство пользователя и способы трансляции сигнала доступа |
| WO2016049230A1 (en) | 2014-09-24 | 2016-03-31 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| WO2016065001A1 (en) | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Recombinant aav variants and uses thereof |
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| AU2015349759B2 (en) | 2014-11-21 | 2022-01-06 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to the central nervous system |
| WO2016126857A1 (en) | 2015-02-03 | 2016-08-11 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
| CA2977355A1 (en) | 2015-02-20 | 2016-08-25 | University Of Iowa Research Foundation | Methods and compositions for treating genetic eye diseases |
| CN106032540B (zh) | 2015-03-16 | 2019-10-25 | 中国科学院上海生命科学研究院 | CRISPR/Cas9核酸内切酶体系的腺相关病毒载体构建及其用途 |
| US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
| EP3280451B8 (en) | 2015-04-08 | 2019-09-25 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Viral gene therapy as treatment for cholesterol storage disease or disorder |
| WO2017015102A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for achieving high levels of transduction in human liver cells |
| IL314171A (en) | 2015-09-28 | 2024-09-01 | Univ Florida | Methods and compositions for antibody-evading virus vectors |
| WO2017066764A2 (en) | 2015-10-16 | 2017-04-20 | William Marsh Rice University | Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses |
| EP3374494A4 (en) | 2015-11-11 | 2019-05-01 | Coda Biotherapeutics, Inc. | CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY |
| US10240145B2 (en) | 2015-11-25 | 2019-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer |
| AU2016366549B2 (en) | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| CN106884014B (zh) | 2015-12-16 | 2020-11-13 | 北京五加和基因科技有限公司 | 腺相关病毒反向末端重复序列突变体及其应用 |
| CA3014637A1 (en) | 2016-02-16 | 2017-08-24 | Mark A. Kay | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
| WO2017151763A1 (en) | 2016-03-01 | 2017-09-08 | Intraop Medical Corporation | Low energy electron beam radiation system that generates electron beams with precisely controlled and adjustable penetration depth useful for therapeutic applications |
| WO2017189963A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CN109640949B (zh) | 2016-07-29 | 2022-11-25 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体和其使用方法 |
| CA3033125A1 (en) | 2016-08-16 | 2018-02-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| US20200316221A1 (en) | 2016-10-13 | 2020-10-08 | University Of Massachusetts | Aav capsid designs |
| KR20190075964A (ko) | 2016-10-13 | 2019-07-01 | 유니버시티 오브 매사추세츠 | Aav 캡시드 설계 |
| US20230048025A1 (en) | 2016-12-22 | 2023-02-16 | Oregon Health & Science University | Adeno associated viral vectors |
| CN108330147A (zh) | 2017-01-20 | 2018-07-27 | 上海吉凯基因化学技术有限公司 | 一种重组腺相关病毒载体生产工艺的建立 |
| US20200270635A1 (en) | 2017-05-05 | 2020-08-27 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| EP3635122A4 (en) * | 2017-06-06 | 2021-03-31 | University of Massachusetts | SELF-REGULATING AAV VECTORS FOR THE SAFE EXPRESSION OF MECP2 IN RETT SYNDROME |
| SI3645551T1 (sl) | 2017-06-27 | 2024-06-28 | Regeneron Pharmaceuticals, Inc. | S tropizmi spremenjeni rekombinantni virusni vektorji in njihova uporaba za tarčni vnos genetskega materiala v človeške celice |
| CN111511375A (zh) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | 用于基因治疗的腺相关病毒载体 |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| DK3684423T5 (da) | 2017-09-20 | 2024-08-26 | 4D Molecular Therapeutics Inc | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf |
| WO2019068854A1 (en) | 2017-10-06 | 2019-04-11 | Ospedale San Raffaele S.R.L. | GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| CA3092107A1 (en) | 2018-02-28 | 2019-09-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for antibody-evading virus vectors |
| WO2019213668A1 (en) | 2018-05-04 | 2019-11-07 | Oregon Health & Science University | Human anti-aav2 capsid polyclonal antibody epitopes |
| AU2018422759B2 (en) * | 2018-05-07 | 2026-01-22 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| JP2021522836A (ja) | 2018-05-15 | 2021-09-02 | ユニバーシティ オブ ワシントンUniversity of Washington | スプライスオパシーの軽減、及びrnaドミナンス障害の治療のための組成物及び方法 |
| US11821009B2 (en) | 2018-05-15 | 2023-11-21 | Cornell University | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery |
| US20210207167A1 (en) | 2018-05-16 | 2021-07-08 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
| WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
| JP2021530218A (ja) * | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| EP3830107A2 (en) | 2018-08-03 | 2021-06-09 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| US11149256B2 (en) | 2018-09-26 | 2021-10-19 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| US12281321B2 (en) * | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN113166208B (zh) * | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| JP2022513618A (ja) | 2018-11-20 | 2022-02-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 血液脳関門の標的化に有用な組成物および方法 |
| MX2021007600A (es) | 2018-12-21 | 2021-08-11 | Univ Pennsylvania | Composiciones para la reduccion de la expresion transgenica especifica de drg. |
| WO2020154324A1 (en) | 2019-01-22 | 2020-07-30 | Ix Layer Inc. | Systems and methods for access management and clustering of genomic or phenotype data |
| AU2020214831B2 (en) | 2019-01-30 | 2025-09-25 | The Broad Institute, Inc. | Systems for evolved adeno-associated viruses (AAVs) for targeted delivery |
| CN119390787A (zh) | 2019-01-31 | 2025-02-07 | 俄勒冈健康与科学大学 | 用于aav衣壳的使用转录依赖性定向进化的方法 |
| CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
| EP3715358A1 (en) | 2019-03-28 | 2020-09-30 | Universität zu Köln | Mutated adeno-associated virus capsid proteins, aav particle comprising the same and liver directed aav vector gene therapy |
| CN114450411A (zh) | 2019-04-01 | 2022-05-06 | 特纳亚治疗股份有限公司 | 具有工程化衣壳的腺相关病毒 |
| TW202102526A (zh) | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
| SG11202111249YA (en) | 2019-04-11 | 2021-11-29 | California Inst Of Techn | Virus compositions with enhanced specificity in the brain |
| CN114269926A (zh) | 2019-04-26 | 2022-04-01 | 美商圣加莫治疗股份有限公司 | Aav工程化 |
| TWI862583B (zh) | 2019-04-26 | 2024-11-21 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
| TW202106705A (zh) | 2019-04-29 | 2021-02-16 | 美商航海家醫療公司 | 用於tau蛋白病變之治療之組合物及方法 |
| WO2020223280A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| WO2021025995A1 (en) | 2019-08-02 | 2021-02-11 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| WO2021073568A1 (en) | 2019-10-16 | 2021-04-22 | Wuxi Apptec (Shanghai) Co., Ltd. | A novel aav variant |
| AU2020398216A1 (en) | 2019-12-04 | 2022-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing blood-brain barrier drug transport by targeting endogenous regulators |
| AU2021218703A1 (en) | 2020-02-14 | 2022-07-28 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating CDKL5 deficiency disorder |
| WO2021202651A1 (en) | 2020-04-01 | 2021-10-07 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| CA3180222A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| AU2021259422A1 (en) | 2020-04-20 | 2022-12-08 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
| US20230193316A1 (en) | 2020-05-01 | 2023-06-22 | The Broad Institute, Inc. | Engineered central nervous system compositions |
| CA3177268A1 (en) | 2020-05-05 | 2021-11-11 | The University Of North Carolina At Chapel Hill | Modified adeno-associated virus 5 capsids and uses thereof |
| US12630842B2 (en) | 2020-05-13 | 2026-05-19 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| JP2023529315A (ja) | 2020-05-26 | 2023-07-10 | シェイプ セラピューティクス インコーポレイテッド | 機能的aavカプシドのハイスループット工学操作 |
| US20230265453A1 (en) | 2020-07-08 | 2023-08-24 | Baylor College Of Medicine | Gene therapy for stxbp1 encephalopathy |
| BR112023001456A2 (pt) | 2020-07-27 | 2023-04-11 | Voyager Therapeutics Inc | Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase |
| EP4199972A4 (en) | 2020-08-21 | 2025-01-15 | Capsida, Inc. | ADENO-ASSOCIATED VIRUS COMPOSITIONS WITH PREFERRED EXPRESSION LEVELS |
| WO2022076750A2 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns or muscle delivery |
| WO2022098699A1 (en) | 2020-11-04 | 2022-05-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tauopathy |
| WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| EP4322976A4 (en) | 2021-04-13 | 2025-06-25 | Capsida, Inc. | AAV COMPOSITIONS WITH HIGH EXPRESSION LEVELS IN THE BRAIN |
| US20250082779A1 (en) | 2021-04-13 | 2025-03-13 | Capsida, Inc. | Adeno-associated virus compositions having increased brain enrichment |
| WO2022221421A2 (en) | 2021-04-13 | 2022-10-20 | Capsida, Inc. | Aav compositions with high brain expression for treating mucopolysaccharidosis ii |
| US20250281643A1 (en) | 2021-04-13 | 2025-09-11 | Capsida, Inc. | Selected aav compositions having preferred brain enrichment |
| AU2022262771A1 (en) | 2021-04-23 | 2023-11-02 | The Trustees Of The University Of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
| EP4334332A4 (en) | 2021-05-04 | 2025-11-12 | California Inst Of Techn | VAA RECOMMENDANTS FOR ADMINISTRATION TO THE CENTRAL NERVOUS SYSTEM AND CEREBRAL VASCULATURE |
| US20240269161A1 (en) | 2021-06-28 | 2024-08-15 | The Board Of Regents Of The University Of Texas System | Methods and compositions for tau reduction gene therapy |
| WO2023004416A1 (en) | 2021-07-23 | 2023-01-26 | California Institute Of Technology | Viral vectors for enhanced ultrasound-mediated delivery to the brain |
| WO2023044306A1 (en) | 2021-09-14 | 2023-03-23 | California Institute Of Technology | Aav capsid variants |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20240382617A1 (en) | 2021-09-21 | 2024-11-21 | Capsida Biotherapeutics, Inc. | Virus compositions to efficiently target the nervous system and the lungs |
| EP4413018A1 (en) | 2021-10-07 | 2024-08-14 | RegenxBio Inc. | Recombinant adeno-associated viruses for targeted delivery |
| IL312340A (en) | 2021-10-28 | 2024-06-01 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
| EP4426716A1 (en) | 2021-11-02 | 2024-09-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2023091934A1 (en) | 2021-11-16 | 2023-05-25 | California Institute Of Technology | Adeno-associated virus compositions having preferred heart and skeletal muscle enrichment |
| WO2023092002A2 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis and disorders associatedwith the spinal cord |
| EP4433169A1 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| US20250049955A1 (en) | 2021-11-17 | 2025-02-13 | Voyager Therapeutics, Inc. | Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| JP2025507338A (ja) | 2022-02-08 | 2025-03-18 | ボイジャー セラピューティクス インコーポレイテッド | Aavカプシドバリアント及びその使用 |
| CA3253473A1 (en) | 2022-03-03 | 2023-09-07 | California Institute Of Technology | COMPOSITIONS AND METHODS FOR CROSSING A BLOOD-BRAIN BARRIER |
| CA3254570A1 (en) | 2022-03-24 | 2023-09-28 | Capsida, Inc. | ADENE-ASSOCIATED VIRUS COMPOSITIONS WITH INCREASED CARDIAC ENRICHEMENT |
| CN119095867A (zh) | 2022-03-24 | 2024-12-06 | 卡西达公司 | 具有优选的脑富集的所选aav组合物 |
| WO2023201207A1 (en) | 2022-04-11 | 2023-10-19 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
| WO2023215546A2 (en) | 2022-05-06 | 2023-11-09 | Capsida, Inc. | Adeno-associated virus compositions having increased brain enrichment |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| EP4526325A4 (en) | 2022-05-17 | 2026-08-05 | Capsida Inc | SELECTED ADENE-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED LEVELS OF CEREBRAL, SPINAL CORD AND/OR CARDIAC EXPRESSION |
| EP4532515A1 (en) | 2022-06-02 | 2025-04-09 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| EP4540268A4 (en) | 2022-06-16 | 2026-08-19 | Capsida Inc | ADENE-ASSOCIATED VIRUS COMPOSITIONS WITH INCREASED CEREBRAL AND/OR CARDIAC ENRICHEMENT |
| WO2023244919A1 (en) | 2022-06-16 | 2023-12-21 | Capsida, Inc. | Adeno-associated virus compositions having increased brain enrichment and decreased liver enrichment |
| US20250243263A1 (en) | 2022-06-22 | 2025-07-31 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CA3263767A1 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER |
| JP2025535203A (ja) | 2022-09-15 | 2025-10-23 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| AU2023363990A1 (en) | 2022-10-19 | 2025-05-08 | Capsida Biotherapeutics, Inc. | Adeno-associated virus compositions having preferred brain enrichment and low liver enrichment |
| AU2023364350A1 (en) | 2022-10-19 | 2025-06-05 | Affinia Therapeutics Inc. | Recombinant aavs with improved tropism and specificity |
| WO2024092164A1 (en) | 2022-10-27 | 2024-05-02 | California Institute Of Technology | Targets for receptor-mediated control of therapeutic biodistribution and efficacy |
| AU2023378899A1 (en) | 2022-11-13 | 2025-06-26 | Alexion Pharma International Operations Limited | Gene therapy for frontotemporal dementia |
| JP2026509271A (ja) | 2023-03-10 | 2026-03-17 | ダイノ セラピューティクス,インコーポレーテッド | カプシドポリペプチドおよびその使用方法 |
| WO2024226761A2 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2024226790A1 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| EP4705324A1 (en) | 2023-05-02 | 2026-03-11 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2024229389A1 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2024229125A2 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to frataxin deficiency |
| WO2024229164A2 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| IL324036A (en) | 2023-05-03 | 2025-12-01 | Voyager Therapeutics Inc | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2024229173A2 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| EP4705486A1 (en) | 2023-05-03 | 2026-03-11 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency |
| JP2026515815A (ja) | 2023-05-03 | 2026-05-19 | ボイジャー セラピューティクス インコーポレイテッド | Cdkl5欠損に関連する障害の治療のための組成物及び方法 |
| JP2026515970A (ja) | 2023-05-04 | 2026-05-19 | ボイジャー セラピューティクス インコーポレイテッド | Aavカプシドバリアント及びその使用 |
| JP2026518667A (ja) | 2023-05-15 | 2026-06-09 | サンガモ セラピューティクス,インコーポレイテッド | 操作された血液脳関門浸透性aavカプシド |
| WO2024238579A2 (en) | 2023-05-15 | 2024-11-21 | Sangamo Therapeutics, Inc. | Fitness maturation of engineered aav capsid stac-102 |
| WO2025038805A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025038800A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to frataxin deficiency |
| WO2025038430A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2025038796A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to cdkl5 deficiency |
| WO2025038802A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| WO2025038795A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025122530A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025122644A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2025122543A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency |
| AR134555A1 (es) | 2023-12-05 | 2026-01-28 | Voyager Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina |
| WO2025122548A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to cdkl5 deficiency |
| WO2025122536A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| WO2025122532A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| WO2025147436A1 (en) | 2024-01-03 | 2025-07-10 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2025235734A2 (en) | 2024-05-09 | 2025-11-13 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
-
2021
- 2021-03-31 US US17/924,800 patent/US12630842B2/en active Active
- 2021-03-31 AU AU2021273447A patent/AU2021273447B2/en active Active
- 2021-03-31 MX MX2022014256A patent/MX2022014256A/es unknown
- 2021-03-31 TW TW110111995A patent/TWI900553B/zh active
- 2021-03-31 EP EP21720894.1A patent/EP4149955A1/en active Pending
- 2021-03-31 CN CN202180049682.3A patent/CN116096734A/zh active Pending
- 2021-03-31 KR KR1020227043585A patent/KR20230022175A/ko active Pending
- 2021-03-31 PE PE2022002647A patent/PE20230767A1/es unknown
- 2021-03-31 BR BR112022023106A patent/BR112022023106A2/pt unknown
- 2021-03-31 CA CA3182970A patent/CA3182970A1/en active Pending
- 2021-03-31 WO PCT/US2021/025061 patent/WO2021230987A1/en not_active Ceased
- 2021-03-31 IL IL298001A patent/IL298001A/en unknown
- 2021-03-31 JP JP2022568852A patent/JP7731909B2/ja active Active
- 2021-10-26 US US17/511,482 patent/US11859200B2/en active Active
-
2022
- 2022-11-11 CO CONC2022/0016156A patent/CO2022016156A2/es unknown
-
2023
- 2023-11-16 US US18/511,290 patent/US12577588B2/en active Active
-
2025
- 2025-08-20 JP JP2025136742A patent/JP2025173511A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4149955A1 (en) | 2023-03-22 |
| WO2021230987A1 (en) | 2021-11-18 |
| US20230203102A1 (en) | 2023-06-29 |
| KR20230022175A (ko) | 2023-02-14 |
| AU2021273447B2 (en) | 2026-03-05 |
| MX2022014256A (es) | 2023-01-11 |
| BR112022023106A2 (pt) | 2023-01-17 |
| IL298001A (en) | 2023-01-01 |
| TWI900553B (zh) | 2025-10-11 |
| JP2023525810A (ja) | 2023-06-19 |
| US20220042044A1 (en) | 2022-02-10 |
| US12577588B2 (en) | 2026-03-17 |
| US11859200B2 (en) | 2024-01-02 |
| AU2021273447A1 (en) | 2022-12-08 |
| JP7731909B2 (ja) | 2025-09-01 |
| US20240200097A1 (en) | 2024-06-20 |
| PE20230767A1 (es) | 2023-05-09 |
| JP2025173511A (ja) | 2025-11-27 |
| TW202208397A (zh) | 2022-03-01 |
| CO2022016156A2 (es) | 2023-01-26 |
| CN116096734A (zh) | 2023-05-09 |
| US12630842B2 (en) | 2026-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932668B2 (en) | Selective recovery | |
| CN116096734A (zh) | Aav衣壳的向性的重定向 | |
| US20230287451A1 (en) | Novel aav capsids and compositions containing same | |
| CA3061368A1 (en) | Compositions and methods of treating huntington's disease | |
| CN116096377A (zh) | 跨物种相容的腺相关病毒组合物及其使用方法 | |
| KR102917057B1 (ko) | 뇌에 지향성을 가지는 aav 돌연변이체 | |
| KR20260011702A (ko) | 조작된 aav 캡시드 stac-102의 적합성 성숙 | |
| EP4135661A1 (en) | Compositions and methods for treatment of neurological disorders | |
| CN121358754A (zh) | 具有外周器官去靶向性的新型嗜神经性腺相关病毒衣壳 | |
| WO2023056367A1 (en) | Slc13a5 gene therapy vectors and uses thereof | |
| US20250197456A1 (en) | Novel aav capsids for targeting nervous system and uses thereof | |
| HK40085441A (en) | Redirection of tropism of aav capsids | |
| WO2025235689A9 (en) | Peptides targeting alpl for blood-brain barrier crossing | |
| WO2025235666A1 (en) | Peptides targeting ldlr for blood-brain barrier crossing | |
| WO2025235682A1 (en) | Peptides targeting tfrc for blood-brain barrier crossing | |
| HK40016209A (en) | Selective recovery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250321 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250321 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250321 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250324 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250401 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250414 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250414 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260324 |